Previous 10 | Next 10 |
home / stock / ngm / ngm articles
Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session. JetBlue’s President & COO Joanna Geragh...
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) shares are trading higher Tuesday after the company confirmed that it has received a non-binding express...
Hsiao Lieu, EVP at NGM Biopharmaceuticals (NASDAQ:NGM), reported a large exercise of company stock options on November 8, according to a new SEC fi...
Irene Perlich, Principal Accounting Officer at NGM Biopharmaceuticals (NASDAQ:NGM), reported a large exercise of company stock options on November ...
Valerie Pierce, SVP at NGM Biopharmaceuticals (NASDAQ:NGM), reported a large exercise of company stock options on November 8, according to a new SE...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focu...
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company ...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focu...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...